Inositide signaling pathways can have a role in the Myelodysplastic Syndromes (MDS) progression to acute myeloid leukemia. Erythropoietin (EPO) is currently used in low-risk MDS, where it successfully corrects anemia in 50-70% of patients. However, some MDS patients are refractory to this treatment and little is known about the exact molecular mechanisms underlying the effect of EPO in these subjects. Here, we investigated the role of inositide pathways in low-risk MDS treated with EPO, mainly focusing on the Akt/PI-PLC (Phosphoinositide-Phospholipase C) gamma1 axis, which is activated by the EPO receptor, and PI-PLCbeta1/Cyclin D3 signaling, as Cyclin D3 is associated with hematopoietic proliferation and differentiation. Interestingly, EPO responder patients showed a specific activation of both the Akt/PI-PLCgamma1 pathway and beta-Globin gene expression, while nonresponders displayed an increase in PI-PLCbeta1 signaling. Moreover, in normal CD34 þ cells induced to erythroid differentiation, PI-PLCbeta1 overexpression abrogated both EPO-induced Akt phosphorylation and beta-Globin expression. Overall, these findings suggest that PI-PLCbeta1 can act as a negative regulator of erythroid differentiation and confirm the involvement of Akt/PI-PLCgamma1 pathway in EPO signaling, therefore contributing to the comprehension of the effect of EPO in low-risk MDS and possibly paving the way to the identification of MDS patients at higher risk of refractoriness to EPO treatment.
INTRODUCTION
Myelodysplastic Syndromes (MDS) are a heterogeneous group of bone marrow (BM) disorders characterized by an ineffective hematopoietic differentiation in one or more of the BM lineages and a variable risk of progression towards acute myeloid leukemia (AML). The impaired stem cell differentiation generally results in anemia, which is one of the major features of MDS patients, mainly in subjects at lower risk of AML evolution. 1 That is why most of the low-risk MDS are now treated with erythropoietin (EPO), which has proven effectiveness in stimulating erythropoiesis and correcting anemia in 50-70% of patients. 2 Nuclear lipid metabolism has an important role in cell proliferation and differentiation, both in normal and pathological conditions. In particular, the activation of the PI3K/Akt/mammalian Target of Rapamycin pathway is often associated with leukemogenesis and it is still one of the most frequent therapeutic targets for hematologic malignancies. 3 Previous works showed the specific activation of Akt in high-risk MDS patients, 4 where also a specific phosphorylation of mammalian Target of Rapamycin and its downstream targets has been demonstrated. 5 Furthermore, in MDS at higher risk of AML evolution it has also been postulated an inverse correlation between the activation of Akt and the expression of Phosphoinositide-Phospholipase C (PI-PLC) beta1, in that low levels of Akt phosphorylation were associated with higher levels of PI-PLCbeta1. 6 Indeed, PI-PLCbeta1 is another key enzyme implicated in signal transduction pathways, affecting cell proliferation and differentiation, 7 possibly through the activation of Cyclin D3. 8, 9 As for this latter, not only it can regulate the progression through the G1/S phase of the cell cycle, but it is also involved in the early stages of the hematopoietic differentiation. 10, 11 In the last few years, a role for nuclear PI-PLCbeta1 in the MDS progression towards AML has been evidenced. 12 In fact, previous studies showed that the expression profile of both PI-PLCbeta1a and PI-PLCbeta1b splicing variants is altered in MDS patients, as compared with healthy subjects. 13 Moreover, it has also been shown that the reduced expression of PI-PLCbeta1b nuclear splicing variant can derive from epigenetic mechanisms, such as hyper-methylation of PI-PLCbeta1 promoter sequence, which results in gene silencing. 14 However, not only epigenetic mechanisms, but also genetic processes affecting PI-PLCbeta1 seem to be involved in the MDS progression to AML, as the presence of a PI-PLCbeta1 mono-allelic deletion in MDS samples has been correlated with a higher risk of evolution into AML. 15 EPO is currently used in the treatment of low-risk MDS patients, mainly with the aim of correcting anemia. 16 However, little is known about the exact molecular mechanisms underlying the effect of EPO in low-risk MDS cells and the reasons why some patients do not respond to this treatment, even though some studies recently investigated whether EPO responder and nonresponder patients have different gene expression profiles. 17 Moreover, EPO is also able to compensate and counteract the ineffective erythropoiesis of MDS patients, therefore regulating cell metabolism, 18, 19 via the activation of the EPO receptor, which is linked to the activation of both Akt and PI-PLCgamma1. 20, 21 Indeed, the balance between cell cycle and apoptosis is critical, especially in low-risk MDS patients, who usually show an increased apoptosis and a low proliferation rate, which may be reversed in case of leukemic evolution. 22 Stemming from these data, in this study we further analyzed the connection between EPO and the lipid signaling pathways. In particular, we focused on PI-PLCbeta1 and its downstream target Cyclin D3, as well as Akt and PI-PLCgamma1. Firstly, we quantified the expression of these signaling molecules in MDS samples before and during the EPO treatment, by semi-quantitative realtime PCR and immunocytochemical analyses. Moreover, we assessed the expression of EPO receptor and Globin genes. In particular, as EPO can induce the erythroid differentiation, we quantified beta-Globin mRNA, whose increase is specifically connected with erythroid differentiation, and gamma-Globin mRNA, which is activated during the early stages of erythropoiesis. 23 Finally, to further investigate the role of PI-PLCbeta1 in erythroid differentiation, we exposed normal human CD34 þ cells to EPO and analyzed the effect of PI-PLCbeta1 overexpression on beta-Globin and PI-PLCgamma1 expression, as well as on Akt phosphorylation.
MATERIALS AND METHODS

Patient characteristics
Bone marrow (BM) samples came from 20 MDS patients and 10 healthy normal volunteers who had given informed consent according to the Declaration of Helsinki. All the samples came from the Department of Hematology and Medical Oncology 'L. e A. Seràgnoli' of the Policlinico S. Orsola-Malpighi, Bologna, Italy. Patients were observed between 2007 and 2011 and the median follow-up was 33.5 months (range 4-39 months). In all the subjects participating in this study, MDS diagnosis was defined according to both French-American-British 24 and World Health Organization (WHO) classifications, 25 while the International Prognostic Scoring System was used to divide the patients into intermediate-1 and low-risk group. 26 However, throughout the text, all of the MDS patients are defined as low-risk MDS.
Patient treatment and evaluation of response
Sixteen of the MDS patients underwent EPO treatment (40-80 000 U once a week or subdivided in two doses), while four patients received best supportive care only. Hematologic response or treatment failure were defined according to the revised International Working Group response criteria for MDS. 27 In particular, the patients who achieved complete remission, partial remission or hematologic improvement were considered responders, whereas the other outcomes were defined as nonresponders.
Isolation of mononuclear cells from BM samples
For in vitro experiments, BM mononuclear cells (MNCs) were isolated by Ficoll-Paque (GE Healthcare, Waukesha, WI, USA) density-gradient centrifugation, according to the manufacturer's instructions. All analyses were performed on samples from patients at baseline, and subsequently once a month during the EPO therapy.
Induction of erythroid differentiation in normal human CD34 þ cells and CD34 þ transfection Normal human CD34 þ BM cells were cultivated for 8 days in a proliferation medium. Then, to induce erythroid differentiation, normal CD34 þ cells were cultivated in a specific differentiation medium for 4 more days, whereas proliferating cells were maintained in proliferation medium for a total of 12 days, as described in the Supplementary Information. After 8 days of proliferation, both types of cells were transfected with an empty vector or a PI-PLCbeta1 vector, as described in the Supplementary Information.
Antibodies and reagents
For all in vitro experiments, antibodies and reagents were purchased from commercial sources, as described in the Supplementary Information.
Nucleic acids extraction
Total RNA was isolated from total MNCs from MDS patients and healthy subjects by using the RNeasy Mini Kit (Qiagen Ltd, Valencia, CA, USA) according to the manufacturer's protocol, then RNA was retro-transcribed as described elsewhere. 14 
Analysis of gene and protein expression
The expression of several genes belonging to the nuclear inositide pathway was quantified by using a specific TaqMan real-time PCR method (Applied Biosystems, Foster City, CA, USA), as described elsewhere. 14 The protein amount was assessed by immunocytochemical analyses, as previously illustrated.
14 Further details can be found in the Supplementary Information.
RESULTS
Patient characteristics
Bone marrow mononuclear cells from 20 patients affected by lowrisk MDS (16 treated with EPO alone and 4 with best supportive care only) were examined. In our case series, median age was 77.5 years (range 57-87 years) for patients treated with EPO alone, and 77.5 years (range 56-82 years) for patients treated with best supportive care only. For all cases, MDS was diagnosed following both French-American-British and WHO classifications, 24, 25 while, according to International Prognostic Scoring System, 26 patients were divided into two risk subgroups: intermediate-1 risk (N ¼ 10) and low-risk (N ¼ 10). However, throughout the text, all of the MDS patients are defined as low-risk MDS. Patient demographics and disease characteristics are summarized in Table 1 .
Study group and clinical response Between March 2007 and December 2011, 16 low-risk MDS patients were treated with EPO alone, whereas four patients were given only supportive care. According to the revised International Working Group criteria, 27 nine of the EPO patients (56.25%) showed a favorable response to the treatment (complete remission, partial remission or hematologic improvement). The remaining seven patients did not respond to EPO, and two of them also evolved into AML within a short time. As for the patients treated only with supportive care, two of them (50%) rapidly evolved into AML, whereas one patient maintained a stable disease and one patient showed a disease progression (Table 1) .
EPO effect on PI-PLCbeta1 and Cyclin D3 gene and protein expression in low-risk MDS patients To determine the effect of EPO therapy on PI-PLCbeta1 splicing variants and Cyclin D3 in low-risk MDS, we studied mRNA samples at baseline and once a month during EPO treatment (Figures 1  and 2 ). PI-PLCbeta1a showed no significant difference neither in EPO responders (Student's t-test, P40.05 versus baseline, 95% confidence interval (CI) À 0.43 to þ 0.48), nor in EPO nonresponder patients (Student's t-test, P40.05 versus baseline, 95% CI À 0.90 to þ 1.51), as compared with the pre-treatment level. On the contrary, the amount of PI-PLCbeta1b showed a statistically significant difference between pre-treatment and the late stages of EPO treatment (Student's t-test, Po0.05 versus baseline, 95% CI À 0.95 to þ 0.22 in patients responding to EPO, Student's t-test, Po0.05 versus baseline, 95% CI þ 0.13 to þ 1.15 in patients refractory to EPO).
Moreover, patients treated with EPO who were refractory to the therapy also showed an increment of Cyclin D3 gene expression after 4-6 months of therapy with a statistically significant difference between pre-and post-treatment (Student's t-test, Po0.05 versus baseline, 95% CI À 0.23 to þ 1.47). In contrast, responder patients did not show any significant alteration in Cyclin D3 levels (Student's t-test, P40.05 versus baseline, 95% CI À 0.49 to þ 0.69).
Due to the limited number of cells, protein expression levels were assessed only by immunocytochemical investigations. The analyses, carried out on samples before and during the therapy, confirmed the results obtained by real-time PCR experiments, that is, only patients refractory to EPO showed an increase in both PI-PLCbeta1 and Cyclin D3 mRNA after 4-6 months of therapy.
As for patients treated with only best supportive care, both realtime PCR and immunocytochemical analyses did not show any significant difference (data not shown).
EPO effect on Akt activation in low-risk MDS patients As the EPO receptor has been demonstrated to activate the Akt signaling, we investigated whether EPO could activate Akt in our low-risk MDS. The levels of total and activated (phosphorylated) Akt in low-risk MDS patients treated with EPO were quantified by immunostaining only, because of the limited amount of material. Total Akt did not show any significant alteration both in responders and nonresponder patients, nor in patients treated with best supportive care only (data not shown). On the other hand, EPO induced a specific upregulation of p-Akt in MDS patients responding to EPO therapy, whereas p-Akt was almost constant in patients refractory to EPO (Figure 3a) .
EPO effect on PI-PLCgamma1 gene and protein expression in low-risk MDS patients Given that the phosphorylation of Akt can also induce an activation of PI-PLCgamma1, we analyzed whether the PI-PLCgamma1 expression was affected by EPO in low-risk MDS samples at baseline and during the therapy. As reported in Figure 4 , patients responding to EPO showed an increment of PI-PLCgamma1 gene expression after 4-6 months of therapy with a statistically significant difference between pre-and post-treatment (Student's t-test, Po0.05 versus baseline, 95% CI þ 0.14 to þ 1.07). In contrast, patients refractory to EPO did not show any significant alteration in PI-PLCgamma1 mRNA (Student's t-test, P40.05 versus baseline, 95% CI À 0.41 to þ 0.47).
As in most cases the number of MDS cells available for each sample was limited, we evaluated the amount of PI-PLCgamma1 protein expression only by immunocytochemical investigations. The analyses were performed on samples before and during the therapy, and confirmed the gene expression results, that is, in responder patients EPO induced an increase in PI-PLCgamma1 protein expression, whereas the amount of PI-PLCgamma1 was almost constant in nonresponders ( Figure 4) .
As for patients treated with only best supportive care, both realtime PCR experiments and immunocytochemical analyses did not show any significant difference (data not shown).
EPO effect on Globin genes in low-risk MDS patients
As the EPO response is often correlated with changes in the expression of Globin genes, we analyzed the amount of betaGlobin and gamma-Globin in our low-risk MDS, at baseline and during the therapy. Patients treated with only best supportive care did not show any significant difference in both beta-Globin and gamma-Globin gene expression (data not shown). On the contrary, EPO significantly affected beta-Globin mRNA in our low-risk MDS ( Figure 5 ). In fact, patients responding to EPO displayed a considerable increment of beta-Globin mRNA, with a statistically significant difference between pre-and post-treatment (Student's t-test, Po0.05 versus baseline, 95% CI þ 0.09 to þ 1.78), whereas patients refractory to EPO showed a significant decrease of beta-Globin gene expression (Student's t-test, Po0.05 versus baseline, 95% CI À 1.28 to þ 0.63). In contrast, neither responder patients nor patients refractory to EPO had significant changes in gamma-Globin gene expression (Student's t-test, P40.05 versus baseline, 95% CI À 0.50 to þ 0.69 for responder patients; Student's t-test, P40.05 versus baseline, 95% CI À 0.24 to þ 0.39 for nonresponder patients).
Expression of EPO receptor during EPO therapy in low-risk MDS patients To assess whether the expression of the EPO receptor was altered in low-risk MDS cases during EPO treatment, we analyzed the amount of EPO receptor in low-risk MDS samples at baseline and during EPO therapy ( Figure 5) . None of the patients treated with EPO showed any significant change in EPO receptor levels, as showed by both gene expression analyses (Student's t-test, P40.05 versus baseline, 95% CI À 1.91 to þ 1.82 for responder patients; Student's t-test, P40.05 versus baseline, 95% CI À 1.44 to þ 1.42 for nonresponder patients) and flow cytometry (data not shown). As for patients treated with only best supportive care, neither real-time PCR nor flow cytometry analyses did show any significant difference (data not shown).
Beta-Globin gene expression in normal CD34 þ cells during erythroid differentiation Normal human CD34 þ BM cells were cultivated in proliferation or differentiation medium, and transfected with empty vector or PI-PLCbeta1. The degree of erythroid differentiation was then assessed by quantifying the amount of beta-Globin gene expression (Figure 5c ). Proliferation medium did not show any significant difference, neither in wild-type cells or in cells transfected with either empty vector or PI-PLCbeta1 (Student's t-test, P40.05 versus baseline, 95% CI À 0.17 to þ 0.33 for wild-type cells; Student's t-test, P40.05 versus baseline, 95% CI À 0.29 to þ 0.34 for cells transfected with empty vector; Student's t-test, P40.05 versus baseline, 95% CI À 0.32 to þ 0.30 for cells transfected with PI-PLCbeta1). In contrast, differentiation medium significantly induced beta-Globin mRNA in wild-type cells (Student's t-test, Po0.05 versus baseline, 95% CI þ 1.15 to þ 2.52) and in cells transfected with empty vector (Student's t-test, Po0.05 versus baseline, 95% CI þ 0.64 to þ 2.00), but not in cells overexpressing PI-PLCbeta1 (Student's t-test, P40.05 versus baseline, 95% CI À 0.52 to þ 0.34). Effect of PI-PLCbeta1 overexpression on Akt activation in normal CD34 þ cells during erythroid differentiation Normal human CD34 þ BM cells were cultivated in proliferation or differentiation medium, and transfected with empty vector or PI-PLCbeta1. The effect of PI-PLCbeta1 overexpression on Akt phosphorylation during erythroid differentiation was then assessed by quantifying the amount of total and activated (phosphorylated) Akt by immunostaining only, because of the limited amount of material. Total Akt did not show any significant alteration both in differentiation and proliferation medium (data not shown), and also proliferation medium did not induce any Akt phoshorylation, neither in wild-type nor in transfected CD34 þ cells (Figure 3c) . In contrast, a specific upregulation of p-Akt was detectable in normal CD34 þ cells cultivated in differentiation medium, wild-type or transfected with empty vector, while CD34 þ cells transfected with PI-PLCbeta1 showed a specific downregulation of p-Akt (Figure 3b Expression of MAPK genes during EPO therapy in low-risk MDS patients As previous studies showed that some genes of the MAPK pathways are downregulated in EPO responder patients, 17 we analyzed the amount of two MAPK genes in our low-risk MDS. As shown in Supplementary Figure 1, DISCUSSION EPO is currently used in low-risk MDS patients with the aim of increasing erythropoiesis and correcting anemia. Nevertheless, some MDS patients are refractory to this therapy, and the molecular mechanisms underlying the effect of EPO in these subjects still need to be clarified, even though some studies recently investigated the gene expression profiles of EPO responders and nonresponders. 17 In this study, two MAPK genes (MAP2K3 and MAP3K11) were specifically downregulated in EPO responders, and this was also confirmed by real-time PCR analyses carried out on our case series.
The effect of EPO is usually connected with the activation of its receptor, which in turn can stimulate several important inositide signaling pathways, such as PI3K/Akt/PI-PLCgamma1, so that the activation of the EPO receptor can be involved in the balance between apoptosis, proliferation and differentiation. This is particularly important in low-risk MDS, that often show an activation of apoptosis and a low proliferation rate, which may be reversed in case of evolution into AML.
Stemming from these data, in this study we analyzed the effect of EPO on nuclear inositide signaling pathways in low-risk MDS patients. First of all, we assessed the expression of PI-PLCbeta1 and its downstream target Cyclin D3, demonstrating that the PI-PLCbeta1/Cyclin D3 axis is downregulated in EPO responder patients after 4-6 months of therapy. This is consistent with previous findings showing that PI-PLCbeta1, after an early transient increase, is downregulated in primary human erythroblasts treated with EPO for up to 96 h, 28 therefore suggesting that PI-PLCbeta1 could be required at the beginning of erythroid differentiation but is dispensable, if not inhibitory, at later stages.
These findings, along with our previous data hinting at an inverse correlation between Akt and nuclear PI-PLCbeta1, lead us to investigate the activation of Akt in the same low-risk MDS patients under treatment with EPO. Interestingly, the Akt phosphorylation in EPO responder cases is in agreement with other previous in vitro studies showing that EPO can induce a nuclear translocation of active Akt, which is required for erythroid differentiation. 29 Furthermore, as Akt phosphorylation is also linked to PI-PLCgamma1 activation, 20 we also studied the expression of this molecule in our low-risk MDS group. Indeed, our results confirm that also PI-PLCgamma1 expression is increased in EPO responder patients, as expected, whereas it is not significantly affected in patients refractory to EPO.
As EPO can activate the erythroid differentiation in low-risk MDS, in this study we also analyzed some key molecules implicated in erythropoiesis: the EPO receptor, and two Globin genes, as the increase in beta-Globin is usually associated with an activation of the erythroid differentiation, whereas gamma-Globin expression in often connected with the early stages of erythropoiesis. 23 Our analyses did not show any significant change in the expression of neither gamma-Globin nor EPO receptor in all of the MDS patients analyzed, either responders or refractory to EPO therapy. In contrast, EPO responders specifically showed an increase in betaGlobin gene expression within the first months of therapy, whereas nonresponders had decreasing levels of beta-Globin mRNA. These results, along with the fact that EPO responders displayed a specific phosphorylation of Akt and a reduction of PI-PLCbeta1 expression, hint at a role for PI-PLCbeta1 as a negative regulator of erythroid differentiation, as also previously hypothesized by in vitro studies in erythroleukemia cells. 30 As a consequence, we induced normal CD34 þ cells to erythroid differentiation, showing that CD34 þ cells overexpressing PI-PLCbeta1 display a downregulation of p-Akt and PI-PLCgamma1 when cultivated in differentiation medium, therefore confirming that PI-PLCbeta1 is a negative regulator of erythroid differentiation and that PI-PLCbeta1 and PI-PLCgamma1 are cross-linked (Figure 3) .
Taken together, our findings could contribute to the comprehension of the molecular mechanisms underlying the effect of EPO treatment in low-risk MDS. Furthermore, the evaluation of the effect of EPO on nuclear inositide signaling molecules could lead to the detection of new molecules associated with the effect of EPO, and might pave the way to new therapeutic strategies, useful in case of EPO refractoriness.
